Hpgc Renmintongtai Pharmaceutical Corporation’s Net Profit Rose 45.6% in First Half of 2023

Hpgc Renmintongtai Pharmaceutical Corporation (哈药集团人民同泰医药股份有限公司) (600829.SH) reported a net profit of 153.4 million yuan in the first half of 2023, up 45.6% year-on-year.

Meanwhile, the company posted 5.3 billion yuan in revenue, up 14.6% year-on-year.

At the end of the reporting period, it had 7.4 billion yuan in total assets and 4.8 billion yuan in total liabilities, with a liability-to-asset ratio of 64.7%.